Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an update

@inproceedings{Fenaux2008AzacitidinePO,
  title={Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an update},
  author={Pierre Fenaux and Ghulam J. Mufti and Eva Hellstr{\"o}m-Lindberg and Valeria Santini and Norbert Gattermann and Guillermo Sanz and A L List and S J Gore and John F Seymour and Jay Backstrom and Lindsey E. Zimmerman and David Mckenzie and C L Beach and Lewis B. Silverman},
  booktitle={Ecancermedicalscience},
  year={2008}
}
Azacitidine (AZA), as demonstrated in the phase III trial (AZA-001), is the first MDS treatment to significantly prolong overall survival (OS) in higher risk MDS pts ((2007) Blood 110 817). Approximately, one-third of the patients (pts) enrolled in AZA-001 were FAB RAEB-T (≥20-30% blasts) and now meet the WHO criteria for acute myeloid leukaemia (AML) ((1999) Blood 17 3835). Considering the poor prognosis (median survival <1 year) and the poor response to chemotherapy in these pts, this sub… CONTINUE READING